{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:16:58Z","timestamp":1790975818792,"version":"4.1.0"},"reference-count":93,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1745,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1755-5949.2010.00211.x","type":"journal-article","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T02:17:33Z","timestamp":1290392253000},"page":"58-65","source":"Crossref","is-referenced-by-count":94,"title":["Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease"],"prefix":"10.1111","volume":"17","author":[{"given":"Yukihiro","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,21]]},"reference":[{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10401239409148985","article-title":"Multiple serotonin receptors: Clinical and experimental aspects","volume":"6","author":"Roth","year":"1994","journal-title":"Ann Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-2007-979623","article-title":"Psychopharmacology of central serotonergic systems","volume":"28","author":"Baumgarten","year":"1995","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"10.1111\/j.1755-5949.2010.00211.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000284623","article-title":"Serotonin-1A anxiolytics: An overview","volume":"22","author":"Feighner","year":"1989","journal-title":"Psychopathology"},{"issue":"Suppl l","key":"10.1111\/j.1755-5949.2010.00211.x-BIB4|cit4","first-page":"52","article-title":"Role of serotonin in therapy of depression and related disorders","volume":"152","author":"Fuller","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-0-306-47593-1_72","volume-title":"Mapping the progress of Alzheimer's and Parkinson's Disease","author":"Ohno","year":"2002"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10571-005-3969-3","article-title":"The serotonin1A receptor: A representative member of the serotonin receptor family","volume":"25","author":"Pucadyil","year":"2005","journal-title":"Cell Mol Neurobiol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","article-title":"The serotonin-1A receptor in anxiety disorders","volume":"66","author":"Akimova","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-005-2240-4","article-title":"5-HT1A receptor expression during memory formation","volume":"181","author":"Luna-Munguia","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molbrainres.2004.06.028","article-title":"Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors","volume":"129","author":"Kusserow","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0028-3908(90)90048-V","article-title":"Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997","volume":"29","author":"Hirose","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1476-5381.1992.tb14431.x","article-title":"Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurons in vitro","volume":"106","author":"Van Den Hooff","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0028-3908(95)00098-Q","article-title":"Characterization of 5-hydroxytryptamine1A properties of flesinoxan: In vivo electrophysiology and hypothermia study","volume":"34","author":"Hadrava","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB14|cit14","first-page":"159","volume-title":"Serotonin in the central nervous system and periphery","author":"Ohno","year":"1995"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjp.0702723","article-title":"The recombinant 5-HT1A receptor: G protein coupling and signalling pathways","volume":"127","author":"Raymond","year":"1999","journal-title":"Brit J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0022-3565(24)38029-2","article-title":"Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats","volume":"288","author":"Tada","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophrenia Bull"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: Focus on serotonin 5-HT1A receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"\u00d6gren","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/j.1875-9114.1988.tb03543.x","article-title":"Buspirone: An update on a unique anxiolytic agent","volume":"8","author":"Jann","year":"1988","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1476-5381.1988.tb11728.x","article-title":"Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus","volume":"95","author":"Schoeffter","year":"1988","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/0306-3623(95)00077-1","article-title":"Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain","volume":"26","author":"Tanaka","year":"1995","journal-title":"Gen Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(24)37788-2","article-title":"F11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential","volume":"287","author":"Koek","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1254\/jjp.59.105","article-title":"Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test","volume":"59","author":"Shimizu","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0028-3908(92)90053-R","article-title":"The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety","volume":"31","author":"Stefa\u0144ski","year":"1992","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"10734","DOI":"10.1073\/pnas.95.18.10734","article-title":"Increased anxiety of mice lacking the serotonin1A receptor","volume":"95","author":"Parks","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.95.24.14476","article-title":"Serotonin receptor 1A knockout: An animal model of anxiety-related disorder","volume":"95","author":"Ramboz","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.npp.1300774","article-title":"Increased fear response to contextual cues in mice lacking the 5-HT1A receptor","volume":"31","author":"Klemenhagen","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0014-2999(89)90803-0","article-title":"Intra-hippocampal buspirone in animal models of anxiety","volume":"168","author":"Kostowski","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0028-3908(91)90009-Z","article-title":"Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic","volume":"30","author":"Kataoka","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(93)90531-L","article-title":"Neural circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat","volume":"249","author":"Schreiber","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2005.12.008","article-title":"5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala","volume":"532","author":"Li","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.2042-7158.1992.tb05521.x","article-title":"Stimulation of postsynaptic 5-HT1A receptors is responsible for the anticonflict effect of ipsapirone in rats","volume":"44","author":"Przegalinski","year":"1992","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/416396a","article-title":"Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult","volume":"416","author":"Gross","year":"2002","journal-title":"Nature"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: Their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.pnpbp.2005.08.007","article-title":"Role of brain norepinephrine in the behavioral response to stress","volume":"29","author":"Morilak","year":"2005","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02244228","article-title":"Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test","volume":"101","author":"Wieland","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0014-2999(94)90816-8","article-title":"The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists","volume":"271","author":"Schreiber","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(95)00254-I","article-title":"Antidepressant-like effect by postsynaptic 5-HT1A receptor activation in mice","volume":"280","author":"Matsuda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","article-title":"5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential","volume":"420","author":"Koek","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/syn.890010511","article-title":"Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain","volume":"1","author":"Blier","year":"1987","journal-title":"Synapse"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0022-3565(25)22932-9","article-title":"Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: Biochemical and electrophysiological studies","volume":"255","author":"Schechter","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0028-3908(91)90175-B","article-title":"Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission","volume":"30","author":"Godbout","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia","volume":"52","author":"Kapur","year":"2001","journal-title":"Ann Rev Med"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB46|cit46","first-page":"213","article-title":"Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone","volume":"49","author":"Ohno","year":"1997","journal-title":"Pol J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1163\/1569391041501906","article-title":"Perospirone hydrochloride: The novel atypical antipsychotic agent with high affinities for 5-HT2, D2 and 5-HT1A receptors","volume":"18","author":"Ishibashi","year":"2004","journal-title":"Biog Amines"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0024-3205(91)90556-Q","article-title":"Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia","volume":"48","author":"Hashimoto","year":"1991","journal-title":"Life Sci"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","article-title":"Alterations in the cortical serotonergic system in schizophrenia: A postmortem study","volume":"42","author":"Gurevich","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(25)38100-0","article-title":"Serotonergic involvement in haloperidol-induced catalepsy","volume":"265","author":"Neal-Beliveau","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0028-3908(98)00162-2","article-title":"Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat","volume":"38","author":"Wadenberg","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: High-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1163\/1569391041501924","article-title":"Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats","volume":"8","author":"Ishibashi","year":"2004","journal-title":"Biog. Amines"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.pnpbp.2008.04.005","article-title":"Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test","volume":"32","author":"Ohno","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophrenia Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0091-3057(94)90451-0","article-title":"Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test","volume":"49","author":"Ohno","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-002-1121-3","article-title":"Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat","volume":"163","author":"Mignon","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuropharm.2006.03.008","article-title":"In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties","volume":"51","author":"Zazpe","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.neuropharm.2008.06.005","article-title":"Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens","volume":"55","author":"Ohno","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1254\/jphs.08313FP","article-title":"Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice","volume":"109","author":"Ohno","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"Suppl 10","key":"10.1111\/j.1755-5949.2010.00211.x-BIB67|cit67","first-page":"15","article-title":"D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET","volume":"60","author":"Remington","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pnpbp.2010.04.005","article-title":"Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders","volume":"34","author":"Shimizu","year":"2010","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/syn.20156","article-title":"The effect of a 5-HT1A receptor agonist on striatal dopamine release","volume":"57","author":"Bantick","year":"2005","journal-title":"Synapse"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0028-3908(03)00304-6","article-title":"Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex","volume":"45","author":"Ago","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","article-title":"Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain","volume":"493","author":"Li","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action","volume":"25","author":"D\u00edaz-Mataix","year":"2005","journal-title":"J Neurosci"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuropharm.2005.01.007","article-title":"Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat","volume":"48","author":"L\u00fcttgen","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.105.092262","article-title":"5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: Interactions with cholinergic and glutamatergic mechanisms","volume":"316","author":"Madjid","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-004-1783-0","article-title":"Intraseptal injection of the 5-HT1A\/5-HT7 agonist 8-OH-DPAT and working memory in rats","volume":"175","author":"Jeltsch","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2006.07.003","article-title":"Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine- generated lesions","volume":"1112","author":"Matsubara","year":"2006","journal-title":"Brain Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neures.2005.03.004","article-title":"A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease","volume":"52","author":"Tomiyama","year":"2005","journal-title":"Neurosci Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-008-1135-6","article-title":"Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat","volume":"199","author":"Dupre","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated Hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0091-3057(95)00142-J","article-title":"Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3 antagonists in the pigeon","volume":"52","author":"Wolff","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0014-2999(96)00275-0","article-title":"The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus","volume":"307","author":"Andrews","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.pbb.2006.11.018","article-title":"The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus","volume":"85","author":"Javid","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.20195","article-title":"Effects of sarizotan on the corticostriatal glutamate pathways","volume":"58","author":"Antonelli","year":"2005","journal-title":"Synapse"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0091-3057(96)00468-6","article-title":"Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: A rple of 5-HT2 receptor blocking activity","volume":"57","author":"Ohno","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3565(24)35135-3","article-title":"Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy","volume":"291","author":"Chartoff","year":"1999","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2006.02.003","article-title":"5-HT1A receptor agonist-mediated protection from MPTP toxicity in mice and macaque models of Parkinson's disease","volume":"23","author":"Bezard","year":"2006","journal-title":"Neurobiol Disease"},{"key":"10.1111\/j.1755-5949.2010.00211.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/jnp.8.4.383","article-title":"Anxiety and Parkinson's disease","volume":"8","author":"Richard","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2010.00211.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1755-5949.2010.00211.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:54:07Z","timestamp":1740714847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2010.00211.x"}},"subtitle":["Therapeutic Role of 5-HT1A Receptors"],"short-title":[],"issued":{"date-parts":[[2010,11,21]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00211.x","relation":{},"ISSN":["1755-5930"],"issn-type":[{"value":"1755-5930","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,21]]}}}